Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Exscientia And Sanofi Will Search For 15 Novel Oncology, Immunology Drugs Under New Pact

Executive Summary

Building on an alliance dating back to 2016, Exscientia and Sanofi will use artificial intelligence and insights gleaned from patient tissue samples to seek out 15 novel therapies.

You may also be interested in...



The Top Five Biopharma Alliances Of Q1

With the help of Biomedtracker’s Dealmaking Quarterly Statistics report, Scrip takes a look at the five biggest alliances by value in the first quarter and how they could shape the future of the companies involved, from big pharma to biotech.

Seismic Hopes To Shake Up Immunology With New Financing

Financing Snapshot: The AI/ML-focused company raised $101m in a series A round and plans to use the funding to develop immunoglobulin- and cell-mediated autoimmune disorder drugs.

Sanofi Pairs Up With Non-Profit Protas In Quest To Cut Clinical Trial Costs

The French major has committed up to £5m for non-profit Protas, which aims to facilitate large clinical studies at a fraction of the usual price and form more pharmaceutical collaborations down the line.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC145670

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel